Sophia Airhart
Advanced Heart Failure and Transplant Cardiology · Springfield, MANPI 1427379825
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (47.7%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. 22 manufacturers reported payments, led by United Therapeutics Corporation at 39.5% of the total. Reporting peaked in 2019 at $26,551 and has fallen 60.8% since, to $10,408 in 2025. Among advanced heart failure and transplant cardiology clinicians in MA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 288 payments — averaging $383.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- United Therapeutics Corporation$44K
- Bayer$24K
- Novartis$14K
- Abbott$10K
- Actelion Pharmaceuticals US, Inc.$6K
- Cvrx, Inc.$5K
- plus $7K from 16 others
Across 93 payments — averaging $10,384 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Livanova USA, Inc.$663K
- Merck$150K
- E.r. Squibb & Sons, L.L.C.$82K
- AstraZeneca$67K
- Abbott$4K
- Amgen$280
What the payments were for
- Consulting fees$37,83034%
- Speaking & faculty fees$52,68848%
- Travel & lodging$8,9918%
- Food & beverage$10,80010%
- Education$940%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| United Therapeutics Corporation | 81 | $43,658 |
| Bayer | 30 | $23,939 |
| Novartis | 18 | $13,678 |
| Abbott | 60 | $10,116 |
| Actelion Pharmaceuticals US, Inc. | 30 | $6,203 |
| Cvrx, Inc. | 12 | $5,356 |
| Merck | 8 | $4,201 |
| Amgen | 9 | $889 |
| Medtronic(2 entities) | 7 | $612 |
| Abiomed | 7 | $523 |
| AstraZeneca | 7 | $318 |
| Pfizer | 3 | $256 |
| Boehringer Ingelheim | 3 | $198 |
| Paragonix Technologies, Inc. | 3 | $160 |
| ZOLL Respicardia, Inc. | 1 | $120 |
| Livanova USA, Inc. | 1 | $77 |
| E.r. Squibb & Sons, L.L.C. | 2 | $27 |
| Biotronik Inc. | 2 | $23 |
| Scpharmaceuticals Inc. | 1 | $23 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $22 |
| Janssen Scientific Affairs, LLC | 1 | $4 |
| Johnson & Johnson | 1 | $2 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Adempas$23,477
- ENTRESTO$13,432
- ORENITRAM$9,552
- UPTRAVI$5,332
- OPSUMIT$5,175
- Barostim Neo System$5,013
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$4,778
- HeartMate 3 Left Ventricular Assist Device$3,284
- TYVASO$2,625
- REMODULIN$1,649
- Impella$368
- CARDIOMEMS$275
- CardioMEMS HF System$224
- MC3 Crescent Jugular Dual Lumen Catheter$220
- COREVALVE EVOLUT R$135
- Assurity Pacemaker$128
- VYNDAQEL$123
- remede System$120
- HeartMate Touch$107
- Quadra Assura CRT Defibrillator$107
How this compares
$110,403 in reported general payments places this provider in the 95th percentile of 35 advanced heart failure and transplant cardiology providers in Massachusetts.
See all advanced heart failure and transplant cardiology providers in Massachusetts →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| WinrevairSotatercept-Csrk | 79 | $1,287,871 |
| OpsumitMacitentan | 79 | $993,476 |
| UptraviSelexipag | 22 | $609,659 |
| Tyvaso DpiTreprostinil | 26 | $597,318 |
| AdempasRiociguat | 43 | $590,135 |
| VyndamaxTafamidis | 16 | $362,131 |
| EntrestoSacubitril/Valsartan | 380 | $337,301 |
| VyndaqelTafamidis Meglumine | 13 | $290,320 |
| JardianceEmpagliflozin | 237 | $220,043 |
| FarxigaDapagliflozin Propanediol | 246 | $201,209 |
| CamzyosMavacamten | 23 | $174,676 |
| EliquisApixaban | 55 | $72,054 |
| Ambrisentan | 16 | $15,559 |
| DapagliflozinDapagliflozin Propanediol | 20 | $9,848 |
| Torsemide | 141 | $3,931 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Actelion Pharmaceuticals US, Inc.Opsumit, Uptravi | $6,203 | $1,603,135101 claims |
| MerckWinrevair | $4,201 | $1,287,87179 claims |
| PfizerVyndamax, Vyndaqel, Eliquis | $256 | $724,50484 claims |
| BayerAdempas | $23,939 | $590,13543 claims |
| NovartisEntresto | $13,678 | $337,301380 claims |
| Boehringer IngelheimJardiance | $198 | $220,043237 claims |
| AstraZenecaFarxiga | $318 | $201,209246 claims |
| E.r. Squibb & Sons, L.L.C.Camzyos | $27 | $174,67623 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 35 advanced heart failure and transplant cardiology providers in Massachusetts.
Other advanced heart failure and transplant cardiology in Springfield
- Leeor JaffeSpringfield$6K
- Cecilia BerardiSpringfield$102
- Pablo Quintero PinzonBoston$137K
- Daniel ZlotoffBoston$96K
- Adam SaltzmanFall River$68K
- Christina Vander PluymBoston$55K
- Richard PattenBurlington$45K
- Monica AhluwaliaBoston$39K
- Stephanie MooreBoston$30K
- Mark TallmanBrighton$28K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.